

(1) Business to be transferred	Partial assets held by GSK in relation to its business producing and selling Lucozade and Ribena. (commercial rights, production facilities, etc.)
(2) Operating performance of the business to be transferred	Net sales: JPY 79.7 billion Gross profit: 37.9 billion (Exchange rate: GBY 1 = JPY 156) (Business year ending December 2012, not audited)
(3) Amount of assets and liabilities to be transferred	Assets: JPY 27.3 billion Debts: none (Exchange rate: GBY 1 = JPY 156) (Business year ending December 2012, not audited)
(4) Amount of cash considered	JPY 210.6 billion (GBP 1,350 million) (tentative) (Exchange rate: GBY 1 = JPY 156) Payment will be made in cash.

3. Overview of GSK

(1) Name	GlaxoSmithKline plc	
(2) Location	980 Great West Road, Brentford, Middlesex, UK	
(3) Representative	Sir Andrew Witty (CEO)	
(4) Businesses	R&D, production and sale of ethical drugs, vaccines, general pharmaceuticals and consumer health care products	
(5) Paid in Capital	GBP 1,349 million (as of December 31, 2012)	
(6) Year Established	December 2000	
(7) Net Assets	GBP 6,747 million (as of December 31, 2012)	
(8) Gross Assets	GBP 41,475 million (as of December 31, 2012)	
(9) Major shareholders and ratio	BlackRock, Inc. 5.52% Legal & General Group Plc 3.12%	
(10) Relationship with SBF	Capital	Nothing noteworthy
	Personal	Nothing noteworthy
	Business	Nothing noteworthy
	Related Party Status	The company is not a related party of SBF. In addition, the company's personnel and affiliated companies are not related parties of SBF.

4. New Company to Acquire the Business

SBF plans to establish a new wholly owned subsidiary in Europe in order to inherit this business. Details will be released as soon as they are finalized.

5. Future Schedule

Below is an overview of the schedule up until the closing.

(1) Decision by the Board of Directors	September 9, 2013
(2) Agreement date	September 9, 2013

(3) Business transfer date	Currently under consideration based on the assumption that the relevant authorities will grant permission following reviews relating to the Anti-Monopoly Act, etc. (currently scheduled for end of December 2013)
----------------------------	--

6. Accounting Overview

This transaction will be treated as an acquisition for accounting purposes.

7. Future Outlook

SBF anticipates that this transfer will have a limited effect on our consolidated results for the business year ending December 2013.

SBF is currently examining the effect it will have on the performance outlook for the following business year and onward, and we will promptly provide notice of the results once they can be released.

(Reference)

Projected Consolidated Results for the Current Period (Ending in December 2013) and Consolidated Results for the Preceding Period (Ending in December 2012)

Units: JPY million

	Consolidated Net Sales	Consolidated Operating Income	Consolidated Ordinary Income	Consolidated Net Income for Current Period
Projected Consolidated Results (Current Period)	1,130,000	75,000	69,000	35,000
Consolidated Results (Preceding Period)	992,160	58,446	54,033	23,385

(Reference)

Estimated EBITDA for the Current Period: JPY 142.0 billion (23.8% YoY)

Estimated Net Income Before Amortization of Goodwill for the Current Period: JPY 59.0 billion (37.0% YoY)

End of Document